Sanofi is deprioritizing a mid-stage treatment for a form of dwarfism and culling three other early-stage studies.
The French pharma deprioritized a Phase 2 drug …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The 24-hour news cycle is just as important to medicine as it is to politics, finance, or sports. At MedPage Today, new information is posted
Curaleaf Reports Second Quarter 2024 Results Second quarter 2024 revenue of $342 million, representing an increase of 2% year-over-year and adjusted gross margin(1) of 48%
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello! Today, we talk